Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 21, 2013
The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activityScott R Armstrong, Christina B Campbell, Carrie L Richardson, et al.Glycobiology|June 11, 2004
Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technologyLawrence J Thomas, Krishnasamy Panneerselvam, David T Beattie, et al.Frontiers in Pharmacology|June 21, 2011
The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic PropertiesDavid T Beattie, Scott R Armstrong, Ross G Vickery, et al.Clinical Pharmacology and Therapeutics|October 23, 2024
First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe DiseaseJulie C Ullman, Ryan A Dick, Daniela Linzner, et al.Bioorganic & Medicinal Chemistry Letters|June 12, 2012
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749Daniel D Long, Scott R Armstrong, David T Beattie, et al.Journal of Medicinal Chemistry|August 12, 2009
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonistsR Murray McKinnell, Scott R Armstrong, David T Beattie, et al.ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor AntagonistDaniel D Long, Scott R Armstrong, David T Beattie, et al.Journal of Crohn'S & Colitis|March 13, 2020
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine ProgrammeWilliam J Sandborn, Deanna D Nguyen, David T Beattie, et al.Bioorganic & Medicinal Chemistry Letters|September 11, 2012
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipationDaniel D Long, Scott R Armstrong, David T Beattie, et al.Science Translational Medicine|January 17, 2024
Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disordersJulie C Ullman, Kevin T Mellem, Yannan Xi, et al.Pageof 2